Centessa Pharmaceuticals Sale to Eli Lilly Faces Probe Over $38 Share Price

The proposed acquisition of Centessa Pharmaceuticals plc by Eli Lilly and Company is now under investigation by law firm Kahn Swick & Foti over the adequacy of its $38.00 per share offer.

"KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company," the firm, which includes former Louisiana Attorney General Charles C. Foti, Jr., Esq., announced.

Under the proposed transaction terms, Centessa shareholders are set to receive the cash payment plus a non-transferrable contingent value right (CVR). The CVR could provide an additional payment of up to $9.00 per share if certain developmental milestones are achieved.

The investigation introduces a layer of uncertainty into the deal, potentially creating legal risks or delays. The core of the probe is to assess whether the total compensation package, including the CVR, fairly values Centessa's drug pipeline and future prospects for its shareholders.

The law firm has invited Centessa shareholders who believe the transaction undervalues the company to discuss their legal rights. This shareholder scrutiny is a critical step in validating the fairness of merger and acquisition agreements, ensuring that the interests of the selling company's investors are protected.

The outcome of the investigation could range from no change in the deal terms to a revised, higher offer from Eli Lilly to appease shareholders and avoid litigation.

This investigation highlights the potential for shareholder pushback in biopharmaceutical M&A, where valuing future drug pipelines is complex. For Centessa investors, the probe could lead to a re-evaluation of the company's worth, while Eli Lilly may face pressure to justify its offer price. The next catalyst will be any formal legal action or a response from either company.

This article is for informational purposes only and does not constitute investment advice.